Coherus Report Results of CHS-201 (biosimilar, ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD
Shots: The COLUMBUS-AMD trial evaluates the clinical efficacy, safety & immunogenicity of CHS-201 (q4w for up to 48wks.) vs Lucentis in a ratio (1:1) in 477 patients with newly diagnosed subfoveal nAMD The results showed a mean BCVA improvement from baseline @8wks. with an equal median change in both treatment groups, patients experienced similar reductions […]